Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY26 results · Oct–Dec 2025
Cohance Lifesciences reported revenue from operations of ₹544.55 crore (up 77.3% from Q3 FY25) and net profit of ₹29.02 crore (down 65.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 544.55 | 307.15 | +77.3% | 555.57 | −2.0% |
| Other income | 6.16 | 15.71 | −60.8% | 15.60 | −60.5% |
| Total income | 550.71 | 322.86 | +70.6% | 571.17 | −3.6% |
| Profit before tax | 40.60 | 109.73 | −63.0% | 83.77 | −51.5% |
| Net profit for the period | 29.02 | 83.29 | −65.2% | 66.39 | −56.3% |
| Attributable to shareholders of the company | 36.72 | 82.88 | −55.7% | 74.08 | −50.4% |
| EPS, basic (₹) | 0.96 | 3.26 | not comparable | 1.94 | −50.5% |
| Net margin (%) | 5.3 | 27.1 | 11.9 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 481.58 | 275.39 | +74.9% | 497.79 | −3.3% |
| Other income | 6.12 | 15.18 | −59.7% | 26.30 | −76.7% |
| Total income | 487.70 | 290.57 | +67.8% | 524.09 | −6.9% |
| Profit before tax | 65.43 | 114.60 | −42.9% | 120.72 | −45.8% |
| Net profit for the period | 47.29 | 86.35 | −45.2% | 94.29 | −49.8% |
| EPS, basic (₹) | 1.24 | 3.39 | not comparable | 2.46 | −49.6% |
| Net margin (%) | 9.8 | 31.4 | 18.9 |
Consolidated
- Filed with BSE
- 12 Feb 2026, 21:11 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2026, 21:11 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE